Booth draft13
Hera dark blue v2

Hera BioLabs, Inc.

Hera is a pioneer in Precision Toxicology™ - Generating high-confidence, clinically-relevant toxicology profiles with greater predictability.

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Lexington, KY, US
  • Currency USD
  • Founded January 2015
  • Employees 10
  • Incorporation Type C-corp
  • Website herabiolabs.com

Company Summary

A major reason for drug development failures is that human specific toxicity is missed in traditionally used pre-clinical cell lines (in vitro testing) and animal models (in vivo testing). Hera has the unique ability to create more predictive animal and cellular models, and is pursuing a two pronged, in vivo and in vitro, strategy.

Team

  • E142cdff f794 40eb b36b bd8d19e5e6db
    Jack Crawford
    CEO

    M.Sc. Biotechnology - University of Pennsylvania - Built revenue at Transposagen the sister company of Hera from $0 to $18MM over a 4 year period, in & out-licensing, IP & technology evaluation, go to market execution, management of scientists and business personnel, grant management and accounting experience

  • 74d4d3bf 0110 4201 9282 d8664d6d5910
    Tseten Yeshi
    VP of R&D

    scientific program management & execution, gene editing and cell culture expert

  • Default avatar
    Chris Chengelis Ph.D.
    Senior Scientific Adviser

    30 years+ experience in the preclinical toxicology industry, facility design, study design and execution, industry & regulatory connections

  • Default avatar
    Eric Ostertag
    Founder & Director

    founder of multiple biotech companies including Transposagen and Poseida Therapeutics, valuation >$100MM

Advisors